Logo

ABVX

Abivax S.A.

ABVX

Abivax S.A. • NASDAQ
$124.83 ▼ -0.68% (-0.85)
Market Cap $9.43 B
52w High $130.25
52w Low $4.77
Dividend Yield 0%
P/E -34.87
Volume 369.23K
Outstanding Shares 75.55M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $2.017M ▼ $95.713M ▼ $-100.784M ▼ -4.997K% ▼ $-1.59 ▼ $-93.594M ▲
Q4-2024 $7.399M ▲ $140.385M ▲ $-94.604M ▼ -1.279K% ▼ $-1.5 ▼ $-131.97M ▼
Q2-2024 $3.393M ▲ $43.392M ▼ $-40.819M ▲ -1.203K% ▲ $-0.65 ▲ $-39.913M ▲
Q4-2023 $2.326M ▲ $92.084M ▲ $-95.787M ▼ -4.118K% ▼ $-1.98 ▼ $-92.084M ▼
Q2-2023 $2.248M $39.206M $-51.953M -2.311K% $-1.45 $-39.206M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $60.946M ▼ $119.641M ▼ $167.921M ▲ $-48.28M ▼
Q4-2024 $144.221M ▼ $205.228M ▼ $164.644M ▲ $40.584M ▼
Q2-2024 $222.317M ▼ $284.492M ▼ $158.022M ▲ $126.47M ▼
Q4-2023 $260.992M ▲ $327.062M ▲ $131.052M ▲ $196.01M ▲
Q2-2023 $114.381M $171.081M $90.592M $80.489M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-100.784M ▼ $-66.618M ▲ $1.269M ▲ $-16.604M ▼ $60.946M ▲ $-66.681M ▲
Q4-2024 $-94.604M ▼ $-68.897M ▼ $1.152M ▼ $-12.115M ▼ $0 $-69.301M ▼
Q2-2024 $-40.819M ▲ $-42.587M ▲ $13.458M ▲ $40.322M ▼ $0 ▼ $-42.706M ▲
Q4-2023 $-95.787M ▼ $-71.162M ▼ $-8.783M ▼ $222.579M ▲ $137.561M ▲ $-71.279M ▼
Q2-2023 $-51.953M $-27.599M $-1.712M $117.99M $87.437M $-28.996M

Five-Year Company Overview

Income Statement

Income Statement Abivax is still a classic clinical‑stage biotech story: almost no product revenue yet and steadily rising operating losses. The income statement is driven by research and development and other operating costs rather than sales. Losses have deepened over the last several years as the company has advanced late‑stage trials, which is normal for this kind of business but means profitability is not in sight until after any potential drug approval and ramp‑up in sales. Earnings per share have been negative throughout, reflecting ongoing dilution and funding of R&D rather than any cash generation for shareholders.

Balance Sheet

Balance Sheet The balance sheet shows a small but real base of assets, heavily dominated by cash and research activity rather than physical equipment. Cash levels built up into 2023 and then declined, suggesting the company has been spending down previous fundraisings. Debt is present but not excessive relative to the size of the company. Equity remains positive but has shrunk recently, which mirrors the accumulated losses. Overall, the balance sheet looks typical for a young biotech: dependent on continued external financing and successful capital raises as development progresses.

Cash Flow

Cash Flow Cash flows are consistently negative from operations, reflecting ongoing spending on clinical trials and overhead with no meaningful offsetting revenue. Free cash flow mirrors this pattern, since Abivax has very limited capital spending needs; the cash burn is almost entirely tied to R&D and operating costs. This means the company’s future depends on its ability to periodically refill its cash reserves through equity, partnerships, grants, or additional financing until and unless a product becomes commercially successful.

Competitive Edge

Competitive Edge Abivax’s competitive position is built around a single, differentiated asset: obefazimod, which uses a novel microRNA‑based approach to controlling inflammation. The drug’s oral dosing and unique mechanism could help it stand out in inflammatory bowel disease, a space crowded with injectable biologics and other targeted therapies from very large pharmaceutical companies. The key strengths are the innovative science, late‑stage ulcerative colitis data, and intellectual property protection. The main competitive vulnerabilities are heavy reliance on one lead product, the dominance of large incumbents with deep sales forces and pricing power, and the need to prove long‑term safety and effectiveness in real‑world use.

Innovation and R&D

Innovation and R&D Innovation and R&D are clearly Abivax’s core assets. The company is pursuing a first‑in‑class mechanism via upregulation of miR‑124, supported by encouraging late‑stage results in ulcerative colitis. It is also testing the same drug in Crohn’s disease and exploring applications in other inflammatory conditions, which could broaden its reach if trials succeed. Behind this, Abivax maintains a proprietary chemical library that may yield follow‑on compounds, but for now the pipeline is heavily concentrated in obefazimod. Future value creation hinges on upcoming trial readouts, regulatory interactions, and the ability to translate strong science into an approvable, commercially viable product.

Summary

Abivax is an early‑stage, research‑driven biotech with a promising but still unproven late‑stage drug for chronic inflammatory diseases. Financially, it remains pre‑revenue, loss‑making, and cash‑consuming, with a balance sheet that can support operations for a time but will likely require further external funding as trials continue. Strategically, its edge comes from a differentiated mechanism, positive late‑stage clinical data in ulcerative colitis, and a focused push in inflammatory bowel disease, set against formidable competition from large pharma and the usual clinical, regulatory, and funding risks of the biotech sector. The company’s trajectory over the next few years will be shaped mainly by clinical outcomes, regulatory milestones, and its success in securing the resources needed to commercialize or partner its lead asset.

NEWS

October 5, 2025 · 11:00 AM UTC

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Read more

September 29, 2025 · 4:05 PM UTC

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Read more

September 23, 2025 · 4:05 PM UTC

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Read more

September 12, 2025 · 11:45 AM UTC

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Read more